Related Articles
Genzyme Pompe Program Update May 2004
Genzyme Pompe Program Update May 2004 Genzyme's Pompe Program has progressed on many fronts over the last 6 months, and we are optimistic that the development of rhGAA will continue to proceed rapidly and responsibly. Infantile Onset Genzyme has two clinical...
IPA /Genzyme Joint Pompe Program Update, August 2004
IPA /Genzyme Joint Pompe Program Update, August 2004 Infantile-Onset Expanded Access Program Enrollment in the Infantile Expanded Access Program is currently on-going. Physicians who may have an infantile-onset Pompe patient should contact Genzyme Medical...
IPA Summary of Genzyme Press Release
IPA Summary of Genzyme Press Release The Genzyme press release about the Pompe program put on GSD net by our IPA board member Allan Muir a week ago will probably raise some questions. With a summary description IPA would like to answer them. Genzyme informed us about...
Letter From Jan van Heek
Letter From Jan van Heek On Saturday, March 9th, 2002, I will be speaking at the VSN (The Dutch Muscular Dystrophy Association, Vereniging Spierziekten Nederland) Annual Patient Conference in The Netherlands. At the conference I will provide a general overview of...
Rescue of enzyme deficiency in embryonic diaphragm in a mouse
Rescue of enzyme deficiency in embryonic diaphragm in a mouse
Long-Term Intravenous Treatment of Pompe Disease With Recombinant Human a-Glucosidase From Milk
Long-Term Intravenous Treatment of Pompe Disease With Recombinant Human a-Glucosidase From Milk
MYOZYME PRODUCED AT THE 2000L BIOREACTOR SCALE TO RECEIVE ACCELERATED APPROVAL
Myozyme Produced at the 2000 L Bioreactor Scale to Receive Accelerated Approval Date: November 17, 2008 New PDUFA Date Set for February 28, 2009 Genzyme Corporation (Nasdaq: GENZ) today announced that the FDA plans an Accelerated Approval for Myozyme® (alglucosidase...
The Myozyme Miracle
The Team Behind the Treatment by Marsha A. Green Yamila Jimenez is a 3-year-old walking miracle. She has Pompe (pronounced pom-PAY) disease, a rare genetic disease that means her body is unable to produce a vital enzyme needed to turn the sugar (glycogen) in her...
FDA APPROVES GENZYMES MYOZYME® FOR ALL PATIENTS WITH POMPE DISEASE
FDA Approves Genzyme's Myozyme® for All Patients with Pompe Disease Date: April 28, 2006 Related Links Myozyme PI FDA Press Release Genzyme Corp. (Nasdaq: GENZ) announced today that the Food and Drug Administration has granted marketing approval for Myozyme®...
United States Pompe Community Update – October 17, 2014
United States Pompe Community Update - October 17, 2014